Promising drug combo shows progress against advanced breast cancer

NCT ID NCT03671330

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tested whether adding the drug ribociclib to standard hormone therapy helps slow the growth of advanced breast cancer in Chinese women. About 327 women with a specific type of breast cancer (HR+, HER2-) took part. The main goal was to see how long the cancer stayed under control. This is not a cure, but aims to manage the disease and delay progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Novartis Investigative Site

Hefei, Anhui, 230001, China
Novartis Investigative Site

Beijing, Beijing Municipality, 100044, China
Novartis Investigative Site

Chongqing, Chongqing Municipality, 404100, China
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050011, China
Novartis Investigative Site

Harbin, Heilongjiang, 150081, China
Novartis Investigative Site

Changsha, Hunan, 410013, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Nanchang, Jiangxi, 330009, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Shengyang, Liaoning, 110016, China
Novartis Investigative Site

Shengyang, Liaoning, 110042, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Kunming, Yunnan, 650106, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310016, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Fuzhou, 350001, China
Novartis Investigative Site

Qingdao, 266000, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Tianjin, 300480, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.